Covidien to repurchase $3B more in company shares

03/25/2013 | Clinica (subscription required)

A plan by Covidien to buy back $3 billion of its stock has been approved by the company's board, a move expected to benefit shareholders over the short term. In August 2011, the company also initiated a similar repurchase program, worth $2 billion.

View Full Article in:

Clinica (subscription required)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Compliance Director
Abbott Laboratories
Santa Clara, CA
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Senior Manager, Compliance
Stryker
Fremont, CA